Dr. Premkamol Patraithikul ist Allgemeinchirurg mit vertiefter Ausbildung in minimalinvasiven Techniken. Dr. Patraithikul erwarb den M.D.-Abschluss an der Khon-Kaen-Universität. Dr. Patraithikul absolvierte die Facharztausbildung in Allgemeinchirurgie an der Thammasat-Universität. Dr. Patraithikul schloss eine Zusatzweiterbildung in laparoskopischer Chirurgie an der Mahidol University (Siriraj Hospital) in Thailand ab.
Klinische Schwerpunkte umfassen laparoskopische und robotergestützte Chirurgie. Das Leistungsspektrum umfasst zudem Allgemeinchirurgie, Adipositas- und Gewichtsmanagement-Chirurgie sowie Eingriffe bei Erkrankungen des Magen-Darm-Trakts.
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
Dr. Nurana Guliyeva ist Gastroenterologin am Zentrum für Biologische Integrative Medizin in Baku. Sie ist auf die Behandlung von viraler Hepatitis, Leberzirrhose und komplexen Autoimmunerkrankungen der Leber spezialisiert. Dr. Guliyeva absolvierte ein Praktikum in Mikrobiologie und Infektionskrankheiten an der Ege-Universität in der Türkei. Ihr Schwerpunkt liegt auf der Verdauungsgesundheit, einschließlich Magen-, Darm- und Bauchspeicheldrüsenerkrankungen.
Der Arzt ist ein hochspezialisierter Chirurg mit umfassender Expertise in onkologischen und metabolischen Eingriffen. Der klinische Schwerpunkt umfasst ein breites Spektrum an Krebsoperationen, einschließlich komplexer Eingriffe bei bösartigen Erkrankungen der Bauchspeicheldrüse, der Gallenwege, des Magens, des Dickdarms und der Schilddrüse sowie spezialisierte Brustchirurgie.
Neben der Onkologie ist der Arzt auf bariatrische und metabolische Chirurgie spezialisiert und bietet fortschrittliche chirurgische Lösungen für das Management von Adipositas und Diabetes. Die Praxis widmet sich der umfassenden chirurgischen Versorgung unter Anwendung evidenzbasierter Techniken zur Behandlung sowohl bösartiger Erkrankungen als auch metabolischer Gesundheitsstörungen.
Dr. Arnulf Ferlitsch ist nationaler Nominierter für den UEGW Rising Star in der Gastroenterologie. Er ist Leiter der Abteilung für Innere Medizin I in Wien.
Professor Schoppmann leitet die Einheit für gastroösophageale Tumoren in Wien. Er ist spezialisiert auf Magen- und Speiseröhrenkrebs sowie Erkrankungen des oberen Gastrointestinaltrakts.
Professor Safadi leitet die Abteilung für Lebererkrankungen am Hadassah Medical Center. Er bietet Magenbiopsien und Kapselendoskopien für eine präzise gastrointestinale Diagnose an.
Der Arzt ist ein führender Gastroenterologe und Spezialist für bariatrische Chirurgie in Europa mit Fachkenntnissen in verschiedenen bariatrischen Operationen. Mit über 3.000 Operationen zur Behandlung von Fettleibigkeit verfügt der Arzt über umfangreiche Erfahrung auf diesem Gebiet.<\/p>
Der Arzt leitet derzeit die Adipositas-Ambulanz im Allgemeinen Krankenhaus Wien und das Zentrum für metabolische Chirurgie im Confraternitaet Privatkrankenhaus.<\/p>
Der Arzt ist Mitglied in mehreren renommierten Organisationen, darunter als Präsident des IFSO-European Chapter, und ist mit der Österreichischen Adipositas-Gesellschaft und der American Society for Metabolic & Bariatric Surgery verbunden.<\/p>
Dr. Yilmaz Bilgic ist Gastroenterologe am JCI-akkreditierten Medipol Acibadem District Hospital in Istanbul. Er ist auf die Behandlung von Morbus Crohn, Colitis ulcerosa und komplexen Lebererkrankungen spezialisiert. Dr. Bilgic absolvierte eine spezialisierte Endoskopie-Ausbildung am Anam Hospital in Südkorea. Zudem schloss er einen Trainingskurs für ERCP am Olympus Training Center in Deutschland ab.
Dr. Cemalettin Aydin ist Professor für Allgemeinchirurgie am Medipol Acibadem District Hospital in Istanbul. Er ist auf Gastroenterologie-Chirurgie und komplexe Gewichtsverlustverfahren spezialisiert. Er absolvierte ein renommiertes Fellowship in Gastroenterologie-Chirurgie am Türkiye High Specialization Hospital.
Dr. Osman Aktas ist Allgemeinchirurg am Avicenna International Hospital in Istanbul. Er absolvierte seine Ausbildung in laparoskopischer Chirurgie in Deutschland. Er ist auf onkologische und metabolische Operationen spezialisiert. Dr. Aktas war zuvor als Chefarzt in mehreren renommierten Militärkrankenhäusern tätig.
Dr. Gokhan Yilmaz ist Allgemeinchirurg am Medipol University Pendik Hospital in Istanbul. Er ist auf kolorektale, gastrointestinale und bariatrische Chirurgie spezialisiert. Dr. Yilmaz war zuvor als Assistenzprofessor an der Istanbul Medipol Universität tätig. Er wurde am Okmeydanı Training and Research Hospital ausgebildet, einer führenden türkischen medizinischen Einrichtung.
Portfolio ansehen
Der Arzt hat 17 Jahre Erfahrung in der oberen GI- und Gewichtsverlustchirurgie und gehört zu den ersten in Indien, die in Los Angeles, USA, in Banded Bypass, Banded Sleeve Gastrectomy und Mini Gastric Bypass ausgebildet wurden. Er führt die innovative Sleeve Gastrectomy mit Duodeno-Jejunal-Bypass durch, die für ihre Wirksamkeit bei der Gewichtsabnahme und der Lösung von Typ-II-Diabetes mellitus bekannt ist, insbesondere für vegetarische Patienten. Ausgebildet in Italien für robotergestützte GI-Chirurgie, nutzt er fortschrittliche Techniken für Präzision und Erholung.<\/p>
Seit 2009 praktiziert er Gewichtsverlust- und metabolische Chirurgie mit minimalinvasiven Techniken, nur 1% seiner Patienten erleben signifikante Morbidität, was den globalen Standards entspricht. Über 90% der diabetischen Patienten führen einen gesunden Lebensstil ohne Insulin oder orale Medikamente.<\/p>
Der Arzt behandelt komplexe bariatrische Fälle, einschließlich Sleeve Gastrectomy, Gastric Bypass und Revision Bariatric Surgery. Er ist versiert in fortgeschrittenen minimalinvasiven und robotergestützten oberen GI- und biliopankreatischen Operationen, mit zahlreichen Publikationen und internationalen Vorträgen.<\/p>
Die Abteilung für bariatrische Chirurgie ist als Exzellenzzentrum von der International Excellence Foundation zertifiziert.<\/p>
Portfolio ansehen
Dozentin Ayse Irem Yasin ist eine fachärztlich ausgebildete medizinische Onkologin am Medipol Acibadem District Hospital. Sie ist auf Magen-Darm-Tumore spezialisiert, bei denen die Gastroskopie mit Biopsie ein wichtiges Diagnoseinstrument darstellt.
Assoc. Prof. Dr. med. Atakan Topçu ist medizinischer Onkologe an der Medipol University und dem Medipol Acıbadem Regional Hospital. Er behandelt solide Tumoren, darunter Lungen-, Brust-, kolorektale, Magen- und neuroendokrine Karzinome. Seine Arbeit umfasst zudem zielgerichtete Therapien, Immuntherapie, geriatrische Onkologie sowie tumorassoziierte Mangelernährung, Kachexie und Sarkopenie.
Er ist Autor von mehr als 50 fachbegutachteten Publikationen. Zu seinen jüngsten Arbeiten zählen eine Studie in Frontiers in Medicine (2024) zu geriatrischen Syndromen und ein Beitrag in Future Oncology (2023) zu Sarkopenie und Angst bei Lungenkrebs. Zudem veröffentlichte er zum CONUT-Score beim Brustkrebs und zur Mangelernährung bei HER2-negativem metastasiertem Magenkrebs.
Dr. Topçu gehört dem Redaktionsbeirat von BMC Cancer an. Er ist Mitglied der Turkish Society of Medical Oncology, der ESMO und der Turkish Geriatrics Society. Ausbildung und Weiterbildung: M.D., Uludağ University; Facharztausbildung Innere Medizin, Marmara University; Fellowship in Medizinischer Onkologie, Bezmialem Vakıf University.
Dr. Svitlana Holovyna ist Gastroenterologin und Ernährungsberaterin mit über 23 Jahren Erfahrung. Sie ist Mitglied der Vereinigung der Diätologen und Gastroenterologen der Ukraine, der Europäischen Leberstudiengesellschaft (EASL) sowie der Gesellschaft für Präventions- und Anti-Aging-Medizin.
Dr. Holovyna diagnostiziert und behandelt Erkrankungen des Verdauungstrakts, Stoffwechselkrankheiten und ernährungsbedingte Probleme. Sie arbeitet integriert und evidenzbasiert. Ihr Schwerpunkt liegt auf der Wiederherstellung der Verdauungsgesundheit, der Behandlung chronischer Erkrankungen und der Verbesserung des Wohlbefindens durch individuelle Ernährungs- und Therapiepläne.